XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock
Employees
Common Stock
Consultants
Common Stock
Paid-in Capital
Employees
Paid-in Capital
Consultants
Paid-in Capital
Accumulated Deficit
Noncontrolling Interest
Employees
Consultants
Total
Balances at Dec. 31, 2023     $ 2     $ 103,879 $ (53,849) $ (1,861)     $ 48,171
Balances (in shares) at Dec. 31, 2023     1,979,413                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Compensation expense related to stock options and restricted stock           36         36
Contra-revenue related to warrants held by licensee           10         10
Shares issued in connection with stock grant         $ 98         $ 98  
Shares issued in connection with stock grant (in shares)   7,800                  
Shares issued in connection with public offering and private placement transactions, net of transaction costs           1,902         1,902
Shares issued in connection with public offering and private placement transactions, net of transaction costs (in shares)     357,889                
Net loss             (6,294) (51)     (6,345)
Balances at Mar. 31, 2024     $ 2     105,925 (60,143) (1,912)     43,872
Balances (in shares) at Mar. 31, 2024     2,345,102                
Balances at Dec. 31, 2023     $ 2     103,879 (53,849) (1,861)     48,171
Balances (in shares) at Dec. 31, 2023     1,979,413                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss                     (15,404)
Balances at Sep. 30, 2024     $ 2     106,078 (69,161) (1,953)     34,966
Balances (in shares) at Sep. 30, 2024     2,358,018                
Balances at Mar. 31, 2024     $ 2     105,925 (60,143) (1,912)     43,872
Balances (in shares) at Mar. 31, 2024     2,345,102                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Compensation expense related to stock options and restricted stock           32         32
Contra-revenue related to warrants held by licensee           10         10
Shares issued in connection with restricted stock grants (in shares)     4,000                
Net loss             195 (34)     161
Balances at Jun. 30, 2024     $ 2     105,967 (59,948) (1,946)     44,075
Balances (in shares) at Jun. 30, 2024     2,349,102                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Compensation expense related to stock options and restricted stock           37         37
Contra-revenue related to warrants held by licensee           9         9
Shares issued in connection with stock grant       $ 10         $ 10    
Shares issued in connection with stock grant (in shares) 1,468                    
Share issued to executives for pro rata portion of base salaries, net of withholding taxes           55         55
Shares issued to executives for pro rata portion of base salaries, net of withholding taxes (in shares)     7,448                
Net loss             (9,213) (7)     (9,220)
Balances at Sep. 30, 2024     $ 2     106,078 (69,161) (1,953)     34,966
Balances (in shares) at Sep. 30, 2024     2,358,018                
Balances at Dec. 31, 2024     $ 2     106,666 (76,244) (2,026)     28,398
Balances (in shares) at Dec. 31, 2024     2,368,072                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Compensation expense related to stock options and restricted stock           33         33
Contra-revenue related to warrants held by licensee           10         10
Additional impact related to fractional shares from reverse stock split     (57)                
Share issued to executives for pro rata portion of base salaries, net of withholding taxes           66         66
Shares issued to executives for pro rata portion of base salaries, net of withholding taxes (in shares)     18,310                
Net loss             (2,797)       (2,797)
Balances at Mar. 31, 2025     $ 2     106,775 (79,041) (2,026)     25,710
Balances (in shares) at Mar. 31, 2025     2,386,325                
Balances at Dec. 31, 2024     $ 2     106,666 (76,244) (2,026)     28,398
Balances (in shares) at Dec. 31, 2024     2,368,072                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss                     (14,777)
Balances at Sep. 30, 2025     $ 5     109,622 (90,928) (2,119)     16,580
Balances (in shares) at Sep. 30, 2025     4,806,776                
Balances at Mar. 31, 2025     $ 2     106,775 (79,041) (2,026)     25,710
Balances (in shares) at Mar. 31, 2025     2,386,325                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Compensation expense related to stock options and restricted stock           54         54
Contra-revenue related to warrants held by licensee           9         9
Shares issued in connection with restricted stock grants (in shares)     21,500                
Warrants issued in connection with refinancing of term loan debt           648         648
Share issued to executives for pro rata portion of base salaries, net of withholding taxes           66         66
Shares issued to executives for pro rata portion of base salaries, net of withholding taxes (in shares)     29,675                
Net loss             (3,988) (3)     (3,991)
Balances at Jun. 30, 2025     $ 2     107,552 (83,029) (2,029)     22,496
Balances (in shares) at Jun. 30, 2025     2,437,500                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Compensation expense related to stock options and restricted stock           40         40
Contra-revenue related to warrants held by licensee           9         9
Share issued to executives for pro rata portion of base salaries, net of withholding taxes           59         59
Shares issued to executives for pro rata portion of base salaries, net of withholding taxes (in shares)     44,416                
Shares issued in connection with public offering and private placement transactions, net of transaction costs     $ 3     1,962         1,965
Shares issued in connection with public offering and private placement transactions, net of transaction costs (in shares)     2,324,860                
Net loss             (7,899) (90)     (7,989)
Balances at Sep. 30, 2025     $ 5     $ 109,622 $ (90,928) $ (2,119)     $ 16,580
Balances (in shares) at Sep. 30, 2025     4,806,776